Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin.
A phase II trial of carboplatin was conducted in 22 patients with advanced germ cell tumors refractory to cisplatin-based chemotherapy. Twenty of 22 patients were evaluable for toxicity and response. Two partial responses and one minor response were seen. The major toxic effect was myelosuppression. Carboplatin has antitumor activity in patients with advanced germ cell tumors refractory to cisplatin, and phase II and III studies of combination chemotherapy are indicated.